Literature DB >> 15298965

Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.

Jason W Barlow1, Marieke Mous, Joe C Wiley, Jennifer M Varley, Guillermina Lozano, Louise C Strong, David Malkin.   

Abstract

Multiple early-onset tumors, frequently associated with germ line TP53 mutations characterize the Li-Fraumeni familial cancer syndrome (LFS). LFS-like (LFS-L) families have lower rates of germ line TP53 alteration and do not meet the strict definition of LFS. This study examined 7 LFS cell lines and 30 LFS and 36 LFS-L primary leukocyte samples for mutations in the proapoptotic p53-regulated gene BAX. No germ line BAX mutations were found. A known BAX polymorphism was observed, yet there was no correlation between polymorphism frequency and TP53 status in either LFS or LFS-L. In summary, alterations of BAX are not responsible for cancers in TP53 wild-type LFS or LFS-L families.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15298965

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  4 in total

1.  Li-fraumeni syndrome.

Authors:  David Malkin
Journal:  Genes Cancer       Date:  2011-04

2.  TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.

Authors:  Raissa Coelho Andrade; Anna Claudia Evangelista Dos Santos; Joaquim Caetano de Aguirre Neto; Julián Nevado; Pablo Lapunzina; Fernando Regla Vargas
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

3.  The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype.

Authors:  Marielle W G Ruijs; Annegien Broeks; Fred H Menko; Margreet G E M Ausems; Anja Wagner; Rogier Oldenburg; Hanne Meijers-Heijboer; Laura J van't Veer; Senno Verhoef
Journal:  Hered Cancer Clin Pract       Date:  2009-02-17       Impact factor: 2.857

4.  The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.

Authors:  Amanda G Silva; Ana C V Krepischi; Peter L Pearson; Pierre Hainaut; Carla Rosenberg; Maria Isabel Achatz
Journal:  Orphanet J Rare Dis       Date:  2014-04-28       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.